Top

BMC Cancer

Published in:

Open Access 01-12-2015 | Research article

Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis

Authors: J. Gurney, C. Shaw, J. Stanley, V. Signal, D. Sarfati

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

The aetiology of testicular cancer remains elusive. In this manuscript, we review the evidence regarding the association between cannabis use and testicular cancer development.

Methods

In this systematic review and meta-analysis, we reviewed literature published between 1^st January 1980 and 13^th May 2015 and found three case–control studies that investigated the association between cannabis use and development of testicular germ cell tumours (TGCTs).

Results/Conclusions

Using meta-analysis techniques, we observed that a) current, b) chronic, and c) frequent cannabis use is associated with the development of TGCT, when compared to never-use of the drug. The strongest association was found for non-seminoma development – for example, those using cannabis on at least a weekly basis had two and a half times greater odds of developing a non-seminoma TGCT compared those who never used cannabis (OR: 2.59, 95 % CI 1.60–4.19). We found inconclusive evidence regarding the relationship between cannabis use and the development of seminoma tumours. It must be noted that these observations were derived from three studies all conducted in the United States; and the majority of data collection occurred during the 1990’s.

Available only for authorised users

Murray RM, Morrison PD, Henquet C, Forti MD. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci. 2007;8(11):885–95.CrossRefPubMed

UNODC. World drug report. New York: United Nations; 2014.

Winter C, Albers P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2011;7(1):43–53.CrossRefPubMed

McGlynn KA, Cook MB. The epidemiology of testicular cancer. Male reproductive cancers: epidemiology, pathology and genetics. New York: Springer; 2009.

Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2014;33(5):623–31. doi:10.1007/s00345-014-1361-y.CrossRefPubMed

McGlynn KA, Trabert B. Adolescent and adult risk factors for testicular cancer. Nat Rev Urol. 2012;9(6):339–49. doi:10.1038/nrurol.2012.61.PubMedCentralCrossRefPubMed

Trabert B, Sigurdson AJ, Sweeney AM, Strom SS, McGlynn KA. Marijuana use and testicular germ cell tumors. Cancer. 2011;117(4):848–53. doi:10.1002/cncr.25499.PubMedCentralCrossRefPubMed

Lacson JCA, Carroll JD, Tuazon E, Castelao EJ, Bernstein L, Cortessis VK. Population-based case–control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer. 2012;118(21):5374–83. doi:10.1002/cncr.27554.PubMedCentralCrossRefPubMed

Daling JR, Doody DR, Sun X, Trabert BL, Weiss NS, Chen C, et al. Association of marijuana use and the incidence of testicular germ cell tumors. Cancer. 2009;115(6):1215–23. doi:10.1002/cncr.24159.PubMedCentralCrossRefPubMed

10.

Huang Y-HJ, Zhang Z-F, Tashkin DP, Feng B, Straif K, Hashibe M. An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers Prev. 2015;24(1):15–31. doi:10.1158/1055-9965.epi-14-1026.CrossRefPubMed

11.

Baade P, Carrière P, Fritschi L. Trends in testicular germ cell cancer incidence in Australia. Cancer Causes Control. 2008;19(10):1043–9.CrossRefPubMed

12.

Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol. 2003;170:5–11.CrossRefPubMed

13.

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12. doi:10.1001/jama.283.15.2008.CrossRefPubMed

14.

Sanderson S, Tatt ID, Higgins JPT. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007;36(3):666–76. doi:10.1093/ije/dym018.CrossRefPubMed

15.

Alam SS, Cantwell MM, Cardwell CR, Cook MB, Murray LJ. Maternal body mass index and risk of testicular cancer in male offspring: a systematic review and meta-analysis. Cancer Epidemiol. 2010;34:509–15.PubMedCentralCrossRefPubMed

16.

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. Quality assessment scales for observational studies. Ottawa, Canada: Ottawa Health Research Institute; 2004.

17.

Burkey MD, Feirman S, Wang H, Choudhury SR, Grover S, Johnston FM. The association between smokeless tobacco use and pancreatic adenocarcinoma: a systematic review. Cancer Epidemiol. 2014;38(6):647–53. http://dx.doi.org/10.1016/j.canep.2014.08.010.CrossRefPubMed

18.

Kirkwood BR, Sterne JA. Essential medical statistics. 2nd ed. Malden: Blackwell Science Ltd; 2003.

19.

Michos A, Xue F, Michels KB. Birth weight and the risk of testicular cancer: a meta-analysis. Int J Cancer. 2007;121:1123–31.CrossRefPubMed

20.

Lip SZL, Murchison LED, Cullis PS, Govan L, Carachi R. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child. 2013;98(1):20–6.CrossRefPubMed

21.

Sterne JA, Bradburn MJ, Egger M. Meta-analysis in stata. Systematic reviews in health care: meta-analysis in context. 2nd ed. London, United Kingdom: Wiley; 2006. p. 347–69.

22.

Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3(10):745–55.CrossRefPubMed

23.

Skeldon SC, Goldenberg SL. Urological complications of illicit drug use. Nat Rev Urol. 2014;11(3):169–77. doi:10.1038/nrurol.2014.22.CrossRefPubMed

24.

Buchan BJ, Dennis ML, Tims FM, Diamond GS. Cannabis use: consistency and validity of self-report, on-site urine testing and laboratory testing. Addiction. 2002;97 SUPPL. 1:98–108.CrossRefPubMed

25.

de Beaurepaire R, Lukasiewicz M, Beauverie P, Castéra S, Dagorne O, Espaze R, et al. Comparison of self-reports and biological measures for alcohol, tobacco, and illicit drugs consumption in psychiatric inpatients. Eur Psychiatry. 2007;22(8):540–8. doi:10.1016/j.eurpsy.2007.05.001.CrossRefPubMed

26.

Jain R, Quraishi R, Majumder P, Pattanayak RD. Comparison of self-report and biological measures for alcohol, tobacco and illicit drug use in consecutive alcohol-dependent patients visiting a tertiary care centre. J Subst Use. 2013;18(4):302–10. doi:10.3109/14659891.2012.674625.CrossRef

27.

Mayet A, Esvan M, Marimoutou C, Haus-Cheymol R, Verret C, Ollivier L, et al. The accuracy of self-reported data concerning recent cannabis use in the French armed forces. Eur J Public Health. 2013;23(2):328–32. doi:10.1093/eurpub/cks108.CrossRefPubMed

28.

Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE, Miech RA. Monitoring the future - national survey results on drug use, 1975–2013: Volume 2, College students and adults ages 19–55. Ann Arbor: Institute for Social Research, The University of Michigan; 2014.

29.

Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- a meta-analysis of 31 studies. BMC Psychiatry. 2014;14:1.CrossRef

30.

Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014;44(4):797–810.CrossRefPubMed

31.

Szoke A, Galliot AM, Richard JR, Ferchiou A, Baudin G, Leboyer M, et al. Association between cannabis use and schizotypal dimensions - a meta-analysis of cross-sectional studies. Psychiatry Res. 2014;219(1):58–66.CrossRefPubMed

Title: Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis
Authors: J. Gurney
C. Shaw
J. Stanley
V. Signal
D. Sarfati
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1905-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results/Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Inter-observer agreement according to three methods of evaluating mammographic density and parenchymal pattern in a case control study: impact on relative risk of breast cancer

The impact of preoperative language mapping by repetitive navigated transcranial magnetic stimulation on the clinical course of brain tumor patients

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy

Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma

SOX4 expression is associated with treatment failure and chemoradioresistance in oral squamous cell carcinoma

Erratum: Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer